Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Nuvation Bio Inc.NYSE: NUVB
Operating Expenses · Q2 FY2026 · quarter ended Jun 2026
Operating expenses grows, but more slowly than its trailing trend
Q2 FY2026 operating expenses of $81.81M rose 24.2% year over year, behind the +30.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 11.0% from the prior quarter. Over 3 fiscal years it compounded at +30.7% a year.
Context
- Operating expenses amounted to 425.3% of revenue in FY2025, down 7112.1 pp from a year earlier.
- Operating expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +24.2% toward the trailing-twelve-month pace of +30.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 267.52M USD
- Year-over-year change
- -54.9%
- 4-year CAGR
- +30.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 267.52M | -54.9% |
| FY2024 | 2024-12-31 | 593.42M | +494.5% |
| FY2023 | 2023-12-31 | 99.82M | -16.6% |
| FY2022 | 2022-12-31 | 119.73M | +28.3% |
| FY2021 | 2021-12-31 | 93.32M | — |
Operating Expenses vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 operating expenses of $297.23M is the 5th highest of the 11 companies compared; the peer median is $255.16M.
- Its year-over-year change of +30.0% is the 5th highest of 11, against a peer median of +24.1%.
- Operating expenses amounts to 174.9% of revenue for NUVB, versus a peer median of 669.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $476.01M | +28.0% | +47.2% | 669.2% | |
| LTM Jun 2026 | $415.76M | +76.1% | +50.9% | — | |
| LTM Mar 2026 | $344.84M | +33.6% | +35.9% | 662.7% | |
| LTM Sep 2026 | $333.75M | +278.1% | +101.5% | 297994.6% | |
| LTM Jun 2026 | $297.23M | +30.0% | +30.7% | 174.9% | |
| LTM Jun 2026 | $256.85M | +16.9% | +75.4% | — | |
| LTM Sep 2026 | $253.48M | -14.5% | +9.2% | 373.5% | |
| LTM Sep 2026 | $217.59M | +20.2% | +38.2% | — | |
| LTM Mar 2026 | $204.75M | +13.6% | -6.4% | 1131.6% | |
| LTM Mar 2026 | $168.69M | +127.4% | +30.3% | 780.5% | |
| LTM Jun 2026 | $130.72M | -27.7% | -15.4% | 42.0% | |
| Peer median (excluding NUVB) | $255.16M | +24.1% | +37.1% | 669.2% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.87M | 62.9M |
| Cost of Revenue | 0 | 0 | 0 | 7.08M | 8.44M |
| Gross Profit | 0 | 0 | 0 | 795K | 54.46M |
| Gross Margin | — | — | — | 10.1% | 86.6% |
| Research & Development | 69.04M | 87.82M | 71.29M | 524.19M | 115.11M |
| Selling, General & Admin | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Operating Expenses | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| EBITDA | (86.66M) | (104M) | (75.58M) | (566.92M) | (189.21M) |
| EBITDA Margin | — | — | — | -7200.7% | -300.8% |
| Operating Income | (93.32M) | (119.73M) | (99.82M) | (592.63M) | (213.06M) |
| Operating Margin | — | — | — | -7527.3% | -338.7% |
| Interest Income | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M |
| Interest Expense | 0 | 0 | 0 | 341K | 13.68M |
| Other Income / Expenses | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M |
| Income Before Tax | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Pre-Tax Margin | — | — | — | -7213.8% | -325.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Net Margin | — | — | — | -7213.8% | -325.3% |
| EPS (Basic) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| EPS (Diluted) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| Weighted Avg Shares | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
| Weighted Avg Shares (Diluted) | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.